BeyondSpring Reports Promising Phase 2 Lung Cancer Study Results

BeyondSpring (BYSI) presented promising phase 2 data in a lung cancer study, showing a median progression-free survival of 6.8 months, a confirmed objective response rate of 18.2%, and a disease control rate of 77.3%. The therapy was generally well tolerated, though 51.1% of participants experienced grade 3 or higher adverse effects. Analysts forecast an average target price of $1.25, indicating a 23.31% downside from the current price of $1.63.

BeyondSpring Inc. (BYSI), a clinical-stage biopharmaceutical company, presented encouraging phase 2 data from their 303 Study at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. The study evaluated the efficacy of a triple combination therapy consisting of Plinabulin, pembrolizumab, and docetaxel in patients with metastatic non-small cell lung cancer (NSCLC) who had progressed after first-line PD-1/L1 inhibitors.

The interim data revealed a median progression-free survival (PFS) of 6.8 months, which is nearly double the standard of care with docetaxel alone (3.7 months) [1]. The confirmed objective response rate (ORR) was 18.2%, higher than the 12.8% seen with the standard of care. The disease control rate (DCR), indicating clinical benefit for the majority of participants, was recorded at 77.3%. The 15-month overall survival (OS) rate was 78%, with the median OS not yet reached at the time of data cut-off.

The therapy was generally well tolerated, though 51.1% of participants experienced grade 3 or higher adverse effects, predominantly gastrointestinal side effects and transient hypertension, with no treatment-related fatalities reported [1].

Analysts forecast an average target price of $1.25, indicating a 23.31% downside from the current price of $1.63. The promising results suggest significant potential for BeyondSpring's Plinabulin in addressing the critical unmet need for more effective treatment options in lung cancer patients who have developed resistance to first-line immunotherapy [1].

References
[1] https://www.morningstar.com/news/globe-newswire/9462288/beyondspring-presents-efficacysafety-data-from-a-phase-2-study-of-pembrolizumab-plus-plinabulindocetaxel-in-metastatic-nsclc-after-progressing-on-first-line-immune-checkpoint-inhibitors-at-2025-asco-annual-meeting